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Cytochrome P450 enzymes metabolize various endo-
genous and exogenous small molecular weight com-
pounds. Transport-associated proteins, such as P-
glycoprotein, multidrug resistance-associated protein
and lung resistance protein are overexpressed in
drug-resistant cell lines, as well as in human tumors
from various histologic origins, including malignant
melanoma. Little is known about the expression and
function of cytochrome enzymes and multidrug
resistance-associated transport proteins in human
skin; therefore, the aim of this study was to analyze
the expression pattern of cytochrome enzymes and
multidrug resistance-associated transport proteins in
proliferating human epidermal keratinocytes under
constitutive conditions and after induction with vari-
ous inducers. Reverse transcription±polymerase
chain reaction revealed constitutive expression of
cytochromes 1A1, 1B1, 2B6, 2E1, and 3A5 in kerati-
nocytes and showed expression of cytochrome 3A4
after incubation with dexamethasone. The expression
of cytochrome 1A1 was enhanced on the mRNA
level after induction with benzanthracene. Reverse
transcription±polymerase chain reaction analysis of
the multidrug resistance-associated transport proteins
revealed constitutive expression of multidrug resist-
ance-associated proteins 1 and 3±6, and lung resist-
ance protein in human epithelial keratinocytes and
was negative for multidrug resistance 1 and 2.
Expression of 1 was seen after induction with dexa-
methasone. Reverse transcription±polymerase chain
reaction results were con®rmed by immunoblots
which showed expression of cytochromes 1A1, 2B6,
2E1, and 3A, multidrug resistance-associated proteins
1, 3, and 5 as well as multidrug resistance 1 after
induction with dexamethasone. Immunohistology
showed positive immuno¯uorescence in skin speci-
mens for cytochromes 1A1, 2B6, 2E1, and 3A and
multidrug resistance-associated protein 1 and multi-
drug resistance 1. Constitutive activity of cyto-
chrome 1A1, 2B, 2E1, and 3A enzymes was
measured by catalytic assays. These results show that
keratinocytes of the human skin express various
transport-associated enzymes and detoxifying meta-
bolic enzymes. Previous studies have revealed that
cytochrome enzymes and transport-associated
proteins play complementary parts in drug dispos-
ition by biotransformation (phase I) and anti-trans-
port (phase III) and act synergistically as a drug
bioavailability barrier. Key words: drug metabolism/drug
transport/skin barrier. J Invest Dermatol 116:541±548,
2001
H
uman skin is both a physical and a biochemical
barrier to the absorption and penetration of
potentially damaging environmental compounds.
Beside the role of the stratum corneum as a most
critical structure for epidermal barrier function there
is increasing evidence indicating that xenobiotic metabolizing
enzymes and transport proteins function as a second ± biochemical
± barrier of the skin (Jugert et al, 1994; Merk et al, 1996; Keeney
et al, 1998b). The metabolic interaction between small molecular
weight compounds and molecular targets in the cell can be
separated at least in these phases: After penetration the xenobiotics
are ®rst chemically activated or inactivated by oxidative reactions
(Guengerich, 1992). The most important family of enzymes
involved in the reactions are the cytochrome P450 enzymes. In
addition to their detoxifying functions they may be involved in
allergic reactions to substances of low molecular weight, e.g.,
contact dermatitis. This has been shown for compounds such as
eugenol, which is metabolized by 3-methylcholantrene inducible
cytochrome P450 (Fischer et al, 1990). Eugenol is a sensitizer only
in those mice which have inducible CYP 1A1 phenotype, giving
further evidence that this enzyme system is important with regard
to the formation of the related antigens and that polymorphism in
the expression and inducibility of this enzyme may be important in
individual risk of developing a sensitization (Merk et al, 1997, 1998;
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Merk, 1998). In phase II the activated or inactivated metabolite is
transformed by epoxide hydrolases, transferases and reductases such
as NAD(P)H-quinone reductase, to convert the insoluble meta-
bolite into a water-soluble substance, thus being able to be
eliminated from the body, e.g., via urine (Lilienblum et al, 1986;
Merk et al, 1991).
After selection for resistance to a single cytotoxic drug, cells may
become cross-resistant to a whole range of drugs with different
structures and targets, a phenomena called multidrug resistance
(MDR; Kool et al, 1997). In human cancer cells, MDR can be
caused by enhanced drug ef¯ux mediated by transporter proteins
such as the MDR1 P-glycoprotein (P-gp), multidrug resistance-
associated protein (MRP), and lung resistance protein (LRP) (Borst
et al, 1997). Expression of transport proteins, such as P-gp, has been
found in normal epithelia, such as those of the gastrointestinal tract,
liver, pancreas, kidney, and reproductive organs (Hunter et al,
1993). In epithelia and endothelia, P-gp is localized in the apical or
luminal region of the cells. The polarized expression of P-gp has led
to the suggestion that its physiologic role is as a secretory
detoxifying system. Thus, in organs such as the kidney, pancreas,
liver, and gastrointestinal tract P-gp would act to secrete toxins and
for gastrointestinal epithelia also limit toxin absorption.
Many studies have investigated the interaction of CYP3A4 or
orthologous CYP3A enzymes, and P-gp, which share many
substrates and/or inhibitors (Kivisto et al, 1995). For example
cortisol, dexamethasone, quinidine, and erythromycin, which
are substrates of in vivo phenotyping assays for CYP3A4 are also
substrates of P-gp (Ged et al, 1989; Wacher et al, 1995; Barnes
et al, 1996; Kim et al, 1999). It has been postulated that
CYP3A and P-gp in intestinal enterocytes may limit the
bioavailability of drugs, with P-gp preventing diffusion of the
parent drugs across the apical brush border membrane and
CYP3A mediating their metabolism (Watkins, 1997). Synergism
between both processes may occur when the metabolites
produced by CYP3A are better substrates for P-gp than the
parent drug (Kolars et al, 1992). Because CYP3A-mediated
metabolism sometimes produces more toxic intermediates, P-gp-
mediated ef¯ux of reactive metabolites could also have import-
ant toxicologic consequences (Lewis et al, 1992).
As CYP3A and P-gp share several substrates and inhibitors,
pharmacokinetic drug±drug interactions are often a composite,
resulting from the interplay of both systems (Wacher et al, 1995;
Benet et al, 1996; Lan et al, 2000). In one study, it was shown that
the anti-fungal ketoconazole or cyclosporine A, which is used in
dermatology for the treatment of psoriasis and atopic dermatitis,
increased the area under the curve for vinca alkaloids most likely by
inhibiting P-gp and CYP3A (Chan, 1998). Similarly, simultaneous
inhibition of P-gp and CYP3A has been postulated to be
responsible for the effects of ketoconazole on the bioavailability
of digoxin or the cysteine protease inhibitor KO2 (Salphati and
Benet, 1998; Zhang et al, 1998).
Skin is a major interface between the environment and the body;
however, little is known about the expression and function of CYP
enzymes and in particular of MDR-associated transport proteins in
this tissue as well as role of their interaction in absorption and
metabolism of xenobiotics. Previous studies revealed that P-gp has
a physiologic function during the migration of dendritic cells from
skin via lymphatic vessels (Randolph et al, 1998) and that
keratinocytes show a high expression of LRP (Izquierdo et al,
1996) and CYP enzymes, such as CYP2B19 (Keeney et al, 1998a).
Therefore, the aim of this study was to analyze the expression
patterns of CYP enzymes and MDR-associated transport proteins
in proliferating human epidermal keratinocytes under constitutive
conditions and after induction with various inducers.
MATERIALS AND METHODS
Chemicals Keratinocyte basal medium, medium supplement kit,
detach kit (Promo Cell, Heidelberg, Germany); 7-pentoxyresoru®n, 7-
ethoxyresoru®n, resoru®n (Pierce, Rockford, IL) bovine serum albumin,
erythromycin, para-nitrophenol, 4-nitrocatechol (Sigma, St Louis, MO);
NADPH, phosphate-buffered saline (PBS; Boehringer, Mannheim,
Germany); nonfat milk powder, Tris (Bio-Rad, Richmond, VI); anti-
CYP1A1, 2B, 2E1, and 3A rabbit (Oxygene, Dallas, TX), monoclonal
anti-CYP2B6, 2E1 (Gentest, Woburn, MA); rabbit CYP1A1, 3A4
(Daiichi Pure Chemicals, Tokyo, Japan) (Fujino et al, 1982; Khan et al,
1987, 1988, 1989; Waxman et al, 1987; Gelboin et al, 1988, 1996);
monoclonal anti-MDR1/C219 (Signet Laboratories, Dedham, MA)
(Chan et al, 1988); monoclonal anti-MRP1/MRPm6 (Chemicon
International, Temecula, CA) (Flens et al, 1994); monoclonal anti-
MRP2/M2III-6 (Alexis Biochemicals, GruÈnberg, Germany) (Kool et al,
1997); monoclonal anti-MRP3/M3II-21 (Kamiya Biomedical, Seattle,
WA) (Kool et al, 1997); monoclonal anti-MRP5/M5I-1 (Kamiya
Biomedical) (Kool et al, 1997); goat-anti-rabbit and goat-anti-mouse IgG
phosphatase labeled, NBT-BCIP Kit (Kirkegaard & Perry, Gaithersburg,
MD); goat anti-mouse IgG ¯uorescein isothiocyanate conjugate and anti-
rabbit IgG TRITC conjugate (Sigma); methanol, n-hexan (Baker,
Deventer, the Netherlands). Other reagents were of highest grade
commercially available.
Keratinocytes Normal human epidermal keratinocytes were obtained
from foreskin by dispase (Boehringer Mannheim) separation of the
epidermal sheet and subsequent trypsin/ethylenediamine tetraacetic acid
digestion and the cells were cultured in low calcium (0.09 mM), serum-
free, keratinocyte medium with bovine pituitary gland extract,
recombinant human epidermal growth factor, insulin, gentamycin sulfate
and amphotericin B as described by the manufacturer (Boehringer
Mannheim). Cells were subcultivated by using the manufacturers detach
kit with Hank's balanced salt solution and trypsin/ethylenediamine
tetraacetic acid. The medium was replaced regularly three times a week.
Cells were used for this study in the second and third passage in late
subcon¯uency. Induction was made by the addition of inducers solved in
dimethyl sulfoxide. The solvent concentration in the medium did not
exceed 0.1%, controls were performed with dimethyl sulfoxide without
inducers. Benz[a]anthracene (BA) was used in a concentration of 10±5 M
over 2 d and dexamethasone as 10±7 M over 3 d.
RNA isolation mRNA was extracted from 5 3 106 cells from ®ve
different donors with the Oligotex Direct mRNA-puri®cation kit
(Qiagen, Hilden, Germany) using the mRNA-enrichment protocol
(Kuribayashi et al, 1988). mRNA concentration of each sample was
measured using the Eppendorf BioPhotometer (Eppendorf, Hamburg,
Germany) and similar amounts of mRNA were used for reverse
transcription.
Reverse transcription±PCR Reverse transcription and PCR was
performed with the GeneAmp RNA PCR kit (Perkin Elmer,
Weiterstadt, Germany) according to the manufacturer's instructions. All
reverse transcription±PCR experiments were performed in duplicate for
each donor. Detection of speci®c mRNA for P450 enzymes and
MDR1, MRP1±6 and LRP was achieved by using primers designed to
amplify at least one intron in the gene to exclude contamination of
cDNA with genomic DNA (Table I). Glyceraldehyde-3-phosphate
dehydrogenase was used as an internal standard as described before
(Hakkola et al, 1994; Kool et al, 1997, 1999; Baron et al, 1998).
Ampli®cation was carried out with 35 cycles of 1 min denaturation at
93°C, 1 min annealing at 54°C and 1 min extension at 72°C.
Ampli®cation was terminated with an extension step of 5 min duration
after the last cycle. PCR products were separated on 1.0% agarose gels
(1 3 Tris-buffered saline) and stained with ethidium bromide.
Cloning of PCR products into a PGEM-T vector PCR products
were extracted from agarose gels using the QIAquick Gel Extraction Kit
(Qiagen). PCR fragments were A-tailed and ligated into the pGEM-T
vector using the PGEM-T Vector system (Promega, Mannheim,
Germany). An aliquot of the ligation mix was transformed into
Escherichia coli JM 109 competent cells (Promega) and plated on LB/amp/
IPTG/X-gal plates. Bacteria were grown until colonies were visible and
blue/white staining could be clearly distinguished. White colonies that
generally contain inserts were picked and bacteria were grown in the
presence of the antibiotic ampicillin. For plasmid preparation the
QIAprep plasmid preparation system (Qiagen) was used.
Sequencing PCR product was sequenced after cloning. Sequencing
was performed using the DYE Primer Cycle sequencing kit (Perkin
Elmer) on an ABI Prism sequencer (Perkin Elmer). Homology searches
in GenBank and EMBL database were done using the BLAST algorithm.
Immunoblot The microsome samples were prepared by
homogenization of the cells through repeated soni®cation on ice in Tris/
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KCl buffer pH 7.4 followed by differential ultracentrifugation. After
30 min centrifugation at 10,000 3 g the supernatant was used for a
subsequent ultracentrifugation for 90 min. The 100,000 3 g pellet was
suspended in Tris/KCl buffer. Protein was estimated according to Lowry
et al (1951). The samples were boiled for 5 min in the presence of
sodium dodecyl sulfate and b-mercaptoethanol according to Laemmli
(1970). We loaded 50 mg microsomal protein into the lanes. Using 12%
polyacrylamide gels with sodium dodecyl sulfate (Novex, Frankfurt,
Germany), blotting was performed on to 0.45 mm cellulose nitrate sheets
(Schleicher & Schuell, Dassel, Germany) according to the method of
Towbin et al (1979) for 1 h with 200 V. Following blocking the
remaining protein binding sites on the membrane with non fat dry milk
powder in PBS, we incubated the blot in the primary antibody solution
(each 1:1000 in PBS) overnight. After subsequent washing steps the blot
was incubated in the secondary antibody solution (each 1:1000 in PBS)
for 4 h. After subsequent washing steps the blot was developed with a
phosphatase staining kit containing nitroblue tetrazolium and bromo-
chloro-indoyl-phosphate for 5 min (Kirkegaard & Perry) to visualize the
bands. Alternatively, the protein bands were detected on an
autoradiography ®lm using the enhanced chemiluminescence western
blotting kit (Amersham, Little Chalfont, UK), according to the
manufacturer's instructions.
Immunostaining CYP1A1-expression was demonstrated in
differentiated keratinocyte multilayers cultured on sterile microscope
slides (Nunc, Wiesbaden, Germany) for 48 h using an indirect
immunoperoxidase technique. In order to detect intracellular CYP1A1,
epitopes were unmasked using methanol and a target unmasking ¯uid
(TUF; Kreatech Diagnostics, Amsterdam, the Netherlands) according to
the manufacturer's instructions. Polyclonal antibodies speci®c for
CYP1A1 (Oxygene, Dallas, TX) were applied (1:400) and detected by
the APAAP method (Dako, Hamburg, Germany). After staining, slides
were covered with Kayser's gelatine and photo-documentation was
performed using a EP64 T Ektachrome ®lm (Kodak, Stuttgart,
Germany).
Immuno¯uorescence For immuno¯uorescent examination human
foreskin specimen were ®xed in 4% formaldehyde (Merck, Darmstadt,
Germany) adjusted to pH 7.4 with sodium hydroxide for 24 h. After
dehydration in alcohol, specimens were embedded in paraplast
(Sherwood Medical, St Louis, MO) and cut into 8 mm sections with a
microtome (Reichert-Jung, Nussloch, Germany). The sections were
deparaf®nated in Histoclear (Shandon, Frankfurt/Main, Germany),
rehydrated in a declining alcohol concentration, washed in distilled water
and prepared for antigen staining by microwave technique, using citrate
buffer solution, pH 6.0, as a buffer for antigen retrieval (Evers and
Uylings, 1994). Then the sections were hydrated in PBS for 10 min,
incubated with 10% bovine serum albumin (Merck) for 30 min, and
with the primary antibodies for another 45 min. After washing the slides
three times with PBS, sections were incubated with secondary
¯uorochrome conjugated antibodies for 45 min, again washed with PBS,
and mounted with Fluorprep (bioMerieux, Marcy l'Etoile, France).
Following, the sections were stored at 4°C in the dark until examination
with ultraviolet light and subsequent photodocumentation using
Kodakchrome 400 ASA slide ®lm (Kodak, Rochester, NY) and a
photomicroscope (DMIL, Leitz, Wetzlar, Germany) equipped with
epi¯uorescence illumination.
As primary antibodies we used polyclonal anti-serum for human CYP
1A1 and CYP 3A (Daiichi Pure Chemicals) and monoclonal antibodies
to CYP 2B6, CYP 2E1 (Gentest), MDR1 (Signet Laboratories,
Dedham, MA), and MRP1 (Chemicon) diluted 1:400 for the detection
of the epitopes.
As a secondary antibody we used rabbit anti-mouse IgG (Fab-speci®c)
¯uorescein isothiocyanate conjugate (Dako) diluted 1:40 and rabbit anti-
goat IgG (Fab-speci®c) CY3-conjugate (SIGMA) diluted 1:30.
Catalytic activities Freshly prepared microsomes from differential
ultracentrifugation were immediately used for the catalytic assays. The
protein determination was made according to Lowry et al (1951) using
bovine serum albumin as standard. Assays were performed under dim red
light. The amount of microsomal protein used was 0.1 mg per
measurement (Jugert et al, 1994).
Table I. Primers used for reverse transcription±PCR analysis
CYP Sense primer location Anti-sense primer location PCR product
1A1 TCACAGACAGCCTGATTGAGA
928±947
GATGGGTTGACCCATAGCTT
1341±1360
433
1A2 TGGCTTCTACATCCCCAAGAAT
1199±1221
TTCATGGTCAGCCCGTAGAT
1488±1507
309
1B1 GTATATTGTTGAAGAGACAG
2423±2442
AAAGAGGTACAACATCACCT
2719±2738
316
2B6/7 CCATACACAGAGGCAGTCAT
1045±1064
GGTGTCAGATCGATGTCTTC
1402±1421
377
2E1 AGCACAACTCTGAGATATGG
925±944
ATAGTCACTGTACTTGAACT
1271±1290
366
3A4 CCAAGCTATGCTCTTCACCG
1279±1298
TCAGGCTCCACTTACGGTGC
1583±1602
324
3A5 TGTCCAGCAGAAACTGCAAA
1065±1084
TTGAAGAAGTCCTTGCGTGTC
1516±1535
471
3A7 CTATGATACTGTGCTACAGT
1041±1060
TCAGGCTCCACTTACGGTCT
1496±1515
475
MDR1 CCCATCATTGCAATAGCAGG
2712±2730
GTTCAAACTTCTGCTCCTGA
2849±2868
157
MRP1 TGGGACTGGAATGTCACG
241±259
AGGAATATGCCCCGACTTC
483±501
261
MRP2 CTGCCCTCTTCAGAATCTTAG
4072±4091
CCCAAGTTGCAGGCTGGCC
4294±4312
241
MRP3 CAGTCAGCCGCTCACCTATC
3458±3477
TCATCCAGTTCAGAGCAAAT
3747±3766
309
MRP4 CCATTGAAGATCTTCCTGG
12±30
GGTGTTCAATCTGTGTGC
243±250
239
MRP5 GGATAACTTCTCAGTGGG
336±353
GGAATGGCAATGCTCTAAAG
697±716
381
MRP6 CCATTGGGCTGTTTGCCTCC
3019±3038
GGTTGACCTCCAGGAGTCC
3237±3255
237
LRP GTCTTCGGGCCTGAGCTGGTGTCG
1546±1569
CTTGGCCGTCTCTTGGGGGTCCTT
1762±1785
240
b-actin ACCCACACTGTGCCCATCTA
488±507
CGGAACCGCTCATTGCC
761±777
290
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Ethoxyresoru®n O-Deethylase (Burke et al, 1985) The substrate 7-
ethoxyresoru®n is de-ethylated to resoru®n in the presence of
nicotinamide adenine dinucleotide phosphate and microsomes. The
product resoru®n is quantitated by a ¯uorocounter.
Pentoxyresoru®n O-Deethylase (Lubet et al, 1985) The assay is the same as
with ethoxyresoru®n, but the substrate is 7-pentoxyresoru®n.
ParaNitrophenol hydroxylase (Koop, 1986) In a CYP 2E1 speci®c reaction
the paranitrophenol is hydroxylated in the presence of ascorbic acid,
nicotinamide adenine dinucleotide phosphate and microsomes to 4-
nitrocatechol, which can be quantitated by visible light.
Erythromycin N-demethylase Using this N-demethylation, which is
speci®c for CYP3A isozymes, the amount of formaldehyde is determined
by the Hantz'sch reaction (Nash, 1953; Jugert et al, 1994)
RESULTS
mRNA expression of CYP enzymes and MDR-associated
proteins Expression of CYP1±3 gene families was studied by
Figure 1. Reverse transcription±PCR of proliferating keratino-
cytes derived from the human epidermis of different donors with
primers speci®c for various P450 enzymes and b-actin. Reverse
transcription±PCR analysis of (a) CYP 1A1, 1B1, 2B6, 2E1, and (b)
CYP3A4, 3A5, and b-actin expression. Lane 1, donor A; lane 2, donor
B; lane 3, donor C; lane 4, donor D; lane 5, donor E; lane 6, DNA
marker pBR322 HaeIII digest. Induction of cells was performed with
dexamethasone (10±7 M) or benzanthracene (10±6 M) for 24 h.
Figure 2. Reverse transcription±PCR of keratinocytes at different
levels of subcon¯uency with primers speci®c for MDR1, MRP1±
6, and LRP. Reverse transcription±PCR analysis of (a) MDR1, MRP1,
MRP3, MRP4, and (b) MRP5, MRP6, and LRP expression. Lanes 1±3,
keratinocytes 60% subcon¯uency (donor A); lanes 4 and 5, keratinocytes
90% subcon¯uency (donor A); lane 6, DNA marker pBR322 HaeIII
digest. Induction of cells was performed with dexamethasone (10±7 M)
for 72 h.
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reverse transcription±PCR in proliferating keratinocytes derived
from the human epidermis of ®ve male donors. Similar amounts of
template mRNA, the same cycle no. (35) and annealing
temperature were used for each reverse transcription±PCR
reaction using different P450 primer pairs. For reverse
transcription±PCR experiments (Fig 1a, b) keratinocytes from
the same degree of con¯uency and from the same pool of cells
(donors A±E) were used for comparisons across different primer
pairs. The results of those reverse transcription±PCR studies are
displayed in Fig 1(a, b). Keratinocytes revealed constitutive
expression of CYP1A1, 1B1, 2B6, 2E1, and 3A5 and showed
expression of CYP3A4 after incubation with dexamethasone
(Fig 1b). The expression of CYP1A1 was enhanced on the
mRNA level after induction with BA (Fig 1a).
Reverse transcription±PCR analysis of the MDR-associated
transport proteins MDR1, MRP 1±6, and LRP revealed
Figure 3. Immunoblots with antibodies against CYP enzymes
and MDR-associated transport proteins. (a) Microsomal preparations
from untreated proliferating human foreskin keratinocytes were separated
on sodium dodecyl sulfate±polyacrylamide gel electrophoresis, blotted on
to nitrocellulose sheets and subsequently treated with antibodies for
cytochromes P450 1A1, 2B6, 2E1, and 3A5, respectively, and an alkaline
phosphatase coupled secondary antibody. Arrows indicate the bands
representing the particular constitutive cytochrome P450 enzyme. Lanes
1±3, donors A±C; lane 4, molecular weight marker: 106, 77, 50.8, 35.6,
28.1, 20.9 kDa. (b) The expression of MDR1, MRP1, MRP3, and
MRP5 was detected via a 7.5% sodium dodecyl sulfate±polyacrylamide
gel electrophoresis using speci®c monoclonal antibodies. Generally,
60 mg of protein are loaded per lane and only for the detection of
MDR1 keratinocytes were induced with dexamethasone (10±7 M) for
72 h. The protein bands were detected on an autoradiography ®lm using
the enhanced chemiluminescence. Lanes 1±6, donors A±E (23).
Rainbow-colored protein molecular weight marker (myosin 220 kDa,
phosphorylase b 97.4 kDa, bovine serum albumin 66 kDa).
Figure 4. Expression of cytochrome P450 by intracellular staining
in differentiated keratinocytes with an antibody against CYP 1A1.
Intracellular immunohistochemical staining of differentiated normal
epidermal keratinocytes after 48 h of Ca2+ preincubation and subsequent
incubation with solvent (a) or (b) benzanthracene (2 3 10±5 M) for
72 h. After APAAP staining with an antibody against CYP1A1, (a)
shows only a few positive cells, whereas in (b) an enhancement of
CYP1A1 expression is shown.
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constitutive expression of MRP1, MRP3, MRP4, MRP5, MRP6,
and LRP in proliferating human epidermal keratinocytes (Fig 2a,
b) and was negative for MDR1 and MRP2 (not shown).
Expression of MDR1 was seen after induction with dexametha-
sone. The level of subcon¯uency of those keratinocytes had no
in¯uence on the expression level of the transport proteins. As
antibodies against some of the MDR-associated transport proteins
analyzed in this study were not available, reverse transcription±
PCR products from MDR1 and MRP1±6 were subcloned and
sequenced (data not shown) to con®rm their identity.
Protein expression of CYP enzymes and MDR-associated
proteins Reverse transcription±PCR results were con®rmed by
immunoblots using speci®c antibodies against cytochrome P450
enzymes, which showed reactivity with CYP 1A1, 2B6, 2E1 and
3A (Fig 3a). Further immunoblots using antibodies against MDR-
associated transport proteins (Fig 3b) revealed the expression of
MRP1, MRP3, and MRP5, and was negative for MRP2 (not
shown). MDR1 was detected in keratinocytes only after induction
with dexamethasone (Fig 3b). Speci®c antibodies against MRP4
and MRP6 were not available.
Immunohistochemistry After pretreatment of keratinocyte
multilayers with ``Target Unmasking Fluid'' it was possible to
show the expression of cytochrome P450 on the protein level by
intracellular staining with speci®c antibodies using the APAAP
method. In Fig 4(a) the antibody speci®c for CYP1A1 reveals the
expression of this enzyme in cultured epidermal keratinocytes of
the untreated control only in a few cells. After induction with BA
the level of cytochrome P450 1A1 expression and the number of
cells expressing CYP1A1 is highly increased (Fig 4b). Using
immuno¯uorescence we were able to identify CYP 1A1, 2B6, 2E1,
3A, MDR1, and MRP1 in keratinocytes of foreskin specimen. The
localization of all CYP enzymes was restricted to the cytoplasm of
the keratinocytes (Fig 5a±d). A preferred staining was seen in the
suprabasal layer of the epidermis. MDR1 was expressed in the cell
membrane of the keratinocytes (Fig 5e). MRP1 was demonstrated
as membrane bound in keratinocytes (Fig 5f).
Functional activity of CYP enzymes in human
keratinocytes As shown in Table II, constitutive activity of
several CYP enzymes were measured by catalytic assays. All of these
activities can be enhanced by inducers, mediating their induction,
e.g., by Ah-receptor (BA) or glucocorticoid responsiveness
elements (DEX), known to increase the activities of CYP1A1 or
2B, 2E1, and 3A enzymes.
DISCUSSION
Interactions of xenobiotics, including drugs and tissues, such as the
skin, are mainly in¯uenced by metabolic capacities and transmem-
brane transport mechanisms. Synergism between both processes
may occur in skin when metabolites produced by CYP enzymes,
such as CYP3A, are better substrates for transport proteins, such as
P-gp than the parent drug, or when P-gp prolongs the duration of
absorption by necessitating the repeated entry of the drug into the
keratinocyte. This process would increase exposure to CYP
enzymes and could also prevent kinetic saturation of these proteins.
Figure 5. Expression of cytochrome P450 and MRP1 by intracellular staining in proliferating keratinocytes. Intracellular
immunohistochemical staining of proliferating normal epidermal keratinocytes. Using antibodies against CYP 1A1 (a), 2B6 (b), 2E1 (c), 3A (d), MDR1
(e), and MRP1 (f) the expression of these proteins were shown by immuno¯uorescence.
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Therefore, in this study the presence of these proteins was carefully
studied on an RNA, protein, morphologic, and catalytic level.
Reverse transcription±PCR, immunoblot, immunohistochemistry,
and catalytic assays revealed that proliferating normal human skin
keratinocytes show the expression of various CYP enzymes,
especially CYP1A1, 1B1, 2B6, 2E1, and 3A. In comparison with
other cells present in human skin, e.g., monocytes (Baron et al,
1998), lymphocytes (Brauers et al, 1998), and ®broblasts (not
published) we measured considerably higher amounts of these
enzymes in keratinocytes. By immuno¯uorescent techniques CYP
1A1, 2B6, 2E1, and 3A were demonstrated to be expressed
dominantly in keratinocytes compared with ®broblasts (data not
shown). In this study we showed the presence and inducibility of
CYP1A1 on the mRNA level by reverse transcription±PCR
(Fig 1a) and on the protein level by immunohistochemistry
(Fig 4a, b). Inducer treatment resulted in a several-fold enhance-
ment of ethoxyresoru®n O-deethylase activity (Table II). Further
experiments showed that phenobarbital increased the CYP2B
catalyzed 7-pentoxyresoru®n O-deethylase and dexamethasone
induced erythromycin N-demethylase, which is preferentially
mediated by CYP3A enzymes. Reverse transcription±PCR analysis
con®rmed these data and showed an induction of CYP3A4 after
incubation with dexamethasone and a constitutive expression of
CYP3A5. This is especially important because Wacher et al (1995)
have shown that CYP3A is the primary CYP subfamily responsible
for the phase I metabolism of over 50% of drugs administered to
humans. These enzymes share a remarkable number of substrates
with transport-associated proteins, such as P-gp. For a broad
spectrum of these drugs, overlapping P-gp/CYP3A substrate
speci®cities and tissue distributions present particular challenges to
drug absorption and delivery to the systemic circulation. Signi®cant
decreases in bioavailability resulting from intestinal CYP3A-
mediated metabolism of drugs, such as cyclosporine, are expected
to be complemented by active extrusion of absorbed drugs through
jejunal P-gp. Analogously, increased CYP and P-gp/MRP levels in
skin tissues can possibly combine to diminish the effective tissue
concentrations of these agents. Recent ®ndings by Sleeman et al
(2000) support this hypothesis. They were able to show that murine
basal layer keratinocytes express functional phosphoglycoproteins
and have the ability to expel the MDR-substrate rhodamine 123.
Interestingly, in human keratinocytes the expression of polyspeci®c
membrane transporters such as P-gp and of CYP enzymes, such as
CYP3A4, was simultaneously upregulated after induction with
dexamethasone (Figs 1b, 2a, 3b).
Reverse transcription±PCR analysis and immunoblots also
revealed a constitutive expression of MRP1, MRP3, MRP4,
MRP5, MRP6, and LRP in human epidermal keratinocytes and
were negative for MDR1 and MRP2. By immuno¯uorescent
techniques the expression of MDR1 and MRP1 was demonstrated
in the membrane of foreskin keratinocytes. MDR1 encodes a large
glycosylated membrane protein, P-gp, that acts as an adenosine
triphosphate-driven ef¯ux pump. Based on its tissue distribution,
P-gp has been proposed to play a part in the protection of the
organism against xenobiotics. van Kalken et al (1993) have shown
that cortisol is transported in an adenosine triphosphate-dependent
process by P-gp expressing cells. Their results suggest a part for P-
gp in steroid hormone transport, possibly to protect the cellular
membranes from potentially toxic concentrations of steroids.
Although increased levels of P-gp are likely to contribute to
MDR, it has become evident that alternative, non-P-gp-mediated
mechanisms of MDR exist. Further studies have discovered the
existence of other transport-associated proteins, such as MRP1 and
MRP2. Both proteins are involved in the transmembrane transport
of glutathione S-conjugates, which is essential for the elimination of
such conjugates from the cell and it was shown in this study that at
least MRP1 is expressed in keratinocytes. From the presence of
MRP in many epithelia lining external surfaces, Flens et al (1996)
suggested that MRP1, like P-gp, may have an excretory function in
protecting the organism against xenobiotics. A search of the human
Expressed Sequence Tag database by Kool et al (1997) found four
transporters related to MRP1 and MRP2 and analyzed the
expression of these genes, called MRP3±6, in normal tissues and
tumor cell lines and all of them were detected in keratinocytes as
shown. Recent studies revealed that MRP3 is an organic anion and
multidrug transporter that confers high-level resistance to metho-
trexate but also has a possible physiologic role as a bile salt
transporter in the small intestine. Other studies showed that
mutations in the MRP6 gene cause pseudoxanthoma elasticum, a
connective tissue disorder affecting elastic structures in the body
including the skin, although the exact pathomechanisms of
pseudoxanthoma elasticum are not completely understood
(Ringpfeil et al, 2000).
The LRP, which was recently identi®ed as the major vault
protein, is present at elevated levels in many non-P-gp MDR cell
lines and, as shown here, in keratinocytes. Vaults are located in the
cytoplasm and it is speculated that they are part of a bidirectional
transport system between nucleus and cytoplasm. Izquierdo et al
(1996) have raised the possibility that vaults are involved in the
transport of drugs into cytoplasmic vesicles or directly out of the
cell. The ubiquitous presence of LRP in a broad panel of highly
specialized cell types, including human keratinocytes suggests that
vaults ful®l a common basic function in all cells, although cell type-
speci®c roles cannot be excluded. The ongoing functional
characterization of vaults is dif®cult, because complex structures
such as complete vaults cannot be simply overproduced by
transfection even if all the subunits have been cloned (Borst et al,
1997).
This study revealed that human epidermal keratinocytes express
various metabolic active enzymes and transport-associated enzymes
and are, therefore, capable of metabolizing and eliminating different
xenobiotics. Especially the discovery of the expression of ATP-
binding cassette transporters, such as MRP 1, 3, 4, 5, and 6 whose
physiologic function has not been completely understood yet,
seems to be a complete new factor in the structure of an active
human skin barrier. Further studies have to characterize the
physiologic role of these proteins in keratinocytes in order to ®nd
Table II. Microsomes (0.1 mg per tube) from human keratinocytes were used for catalytic assaysa
7-Ethoxy-resoru®n-
O-deethylase CYP1A
7-Pentoxy resoru®n-
O-deethylase CYP2B
Para-Nitro-Phenol-
Hydroxylase CYP2E
Erythro-mycin-
N-demethylase CYP3A
Basal activity 10.69 1.435 1.808 3.256
Induced activity 213.44 5.103 3.199 7.725
Inducer 20 mM benz[a]anthracen 4 mM phenobarbital 0.5 M ethanol 5 mM dexamethasone
Activity in
min per mg
protein
pmol resoru®n pmol resoru®n nmol 4-nitrocatechol nmol formaldehyde
aEthoxyresoru®n is O-deethylated to resoru®n by CYP1A enzymes. Pentoxyresoru®n is O-deethylated to resoru®n by CYP2B enzymes. ParaNitrophenol is hydroxylated
to 4-nitrocatechol mainly by CYP2E1. Erythromycin is N-demethylated through CYP3A enzymes and the generated formaldehyde is determined by the Hantz'sch reac-
tion.
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out if biotransformation and anti-transport do act synergistically as a
drug bioavailability barrier in human skin.
These studies were supported by a grant from the DFG (BA 1803/1±1), START
(26/2000) and TV48 of IZKF BIOMAT.
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